Thursday, October 20, 2022 10:00:55 PM
1776 - where have you been as of late?
I have a very good friend, who, like many other Americans is perplexed where the USA is headed - I asked him how he handles it. He simply said he is happily ignorant. Is this your frame of mind now 1776? Staying away or are you out?
Me - here to the end. Down so much already it would be silly to sell. Have a few concerns in short term though - will further dilution take us to <$1? Still as far as I can see, no real revenue stream. Could we be delisted soon?
• I wonder why Dr. Ji was at NYSE a few months back?
• Will we as shareholders of SRNE have any benefit from the spinoff of Scilex?
•There are 76 positions listed on our website - how will these positions be paid for if filled?
• It is obvious our current team is unable to drag ANYTHING over finish line - how can we convince board to fire inept staff and use external services such as Cardinal Health? They offer Drug Development and Regulatory Consulting
and will partner with a SRNE to develop the best regulatory pathway for a product, through every stage of its lifecycle.
• Haven't heard a PEEP from our CFO or even Tommy T! Wonder what they have been up to!?
I love our tagline: "Medicines For Saving Life" - I guess we can dream about that as I doubt we've saved a single one.
Cheers, Andecker
Recent SRNE News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 10:26:26 AM
- Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the A • GlobeNewswire Inc. • 06/05/2023 01:00:00 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM